Enhertu 100 mg Powder for concentrate for solution for infusion.
PDF Leaflet Revision Date: 12 September 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of unresectable or metastatic HER2-positive and HER2-low breast cancer, and advanced HER2-positive gastric cancer.
Dosage (summary)
Breast cancer: 5.4 mg/kg IV every 3 weeks; Gastric cancer: 6.4 mg/kg IV every 3 weeks.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Embryo-foetal toxicity; contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Ritonavir
- Itraconazole
Contraindications
- Hypersensitivity to active substance or excipients
Common side effects
- Nausea
- Fatigue
- Vomiting
- Neutropenia
- Alopecia
Counselling Points
- Monitor for respiratory symptoms
- Use effective contraception
- Report any adverse reactions immediately
Serious warnings
- Interstitial lung disease
- Severe infusion reactions
- Cardiac function monitoring required
Important Disclaimer
The Enhertu 100 mg Powder for concentrate for solution for infusion. professional information leaflet below is the property of Astrazeneca Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
